You are here
The use of myocardial perfusion imaging (MPI) has spiked over the past four decades and along with it individual patient dose. A comprehensive effort to reduce that dose could reduce unnecessary procedures and reduce the risk of downstream cancers, according to a meta-analysis published in the April issue of the Journal of Nuclear Medicine.
A novel amino acid agent could zero in on cancerous tumors and provide a much longer half-life than the status quo, according to a study published in the April issue of the Journal of Nuclear Medicine.
The origins of foot pain are often unclear and present a challenge for clinicians seeking to treat the underlying cause. PET/MR with F-18 fluoride may turn out to be the best modality to solve the mystery, the Society of Nuclear Medicine and Molecular Imaging announced this month.
Over the past several years, studies involving theranostic nanoparticles have provided several shining examples of where molecular cancer imaging is going.
A new study suggests the use of not only three, but four or more PET/CT evaluations during follow-up for lung cancer, as the research revealed that additional PET/CTs changed patient management in 28.1 percent of cases, the Society of Nuclear Medicine and Molecular Imaging (SNMMI) announced Feb. 18.
FDG PET imaging of inflammation has proven to be very useful when evaluating atherosclerosis, but researchers have not yet come to a consensus about the proper protocol for this up-and-coming molecular imaging technique.
Amyloid imaging can tell Alzheimer’s disease (AD) and frontotemporal dementia (FTD) apart because FTD typically does not show the same pattern of amyloid, right? Not so fast, say brain researchers.
CHICAGO—Recent CMS decisions related to oncologic use of FDG and amyloid imaging have already left their mark on the radiopharmaceutical industry, according to major market stakeholders at this year's Radiological Society of North America (RSNA) meeting.
CHICAGO—The disciplines of radiomics and genomics are being spliced for specialized tumor mapping that moves toward a less invasive, higher-tech supplement, and perhaps one day an alternative to biopsy, according to a molecular imaging symposium presented Dec. 2 at the Radiological Society of North America’s (RSNA) 99th annual meeting.
The predictive value of FDG PET for therapy response has been proven for a range of treatments for non-small cell lung cancer (NSCLC), now including concomitant chemoradiotherapy, which requires careful patient selection due to associated morbidity, according to a study published July 17 in the Journal of Nuclear Medicine.